actigall
| Product dosage: 150mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | $2.00 | $60.08 (0%) | 🛒 Add to cart |
| 60 | $1.84 | $120.17 $110.15 (8%) | 🛒 Add to cart |
| 90 | $1.65 | $180.25 $148.21 (18%) | 🛒 Add to cart |
| 120 | $1.56 | $240.34 $187.26 (22%) | 🛒 Add to cart |
| 180 | $1.47 | $360.51 $264.37 (27%) | 🛒 Add to cart |
| 360 | $1.38
Best per tab | $721.01 $495.70 (31%) | 🛒 Add to cart |
| Product dosage: 300mg | |||
|---|---|---|---|
| Package (num) | Per tab | Price | Buy |
| 30 | $4.01 | $120.17 (0%) | 🛒 Add to cart |
| 60 | $3.30 | $240.34 $198.28 (18%) | 🛒 Add to cart |
| 90 | $3.08 | $360.51 $277.39 (23%) | 🛒 Add to cart |
| 120 | $2.96 | $480.68 $355.50 (26%) | 🛒 Add to cart |
| 180 | $2.90
Best per tab | $721.01 $521.73 (28%) | 🛒 Add to cart |
Synonyms | |||
Actigall, known generically as ursodiol or ursodeoxycholic acid, is a naturally occurring bile acid used therapeutically as a prescription medication rather than an over-the-counter dietary supplement. It’s primarily indicated for dissolving certain types of gallstones and managing specific chronic liver conditions. Unlike many hepatotoxic bile acids, ursodiol is hydrophilic and cytoprotective, making it a cornerstone in gastroenterology and hepatology practice for patients who aren’t surgical candidates or need long-term liver protection.
I remember when I first encountered Actigall during my hepatology rotation—we had a patient, 54-year-old Maria, with primary biliary cholangitis (PBC) whose alkaline phosphatase was climbing despite first-line therapy. My attending handed me the Actigall package insert and said, “This is going to be her lifeline.” We started her on 13-15 mg/kg divided twice daily, and within months, her pruritus improved dramatically. That’s when I realized this wasn’t just another medication; it was fundamentally altering bile acid pool composition.
Actigall: Effective Gallstone Dissolution and Liver Protection - Evidence-Based Review
1. Introduction: What is Actigall? Its Role in Modern Medicine
Actigall contains the active pharmaceutical ingredient ursodiol, a tertiary bile acid that constitutes approximately 1-3% of the human bile acid pool. What is Actigall used for? Primarily, it’s indicated for patients with radiolucent, non-calcified gallstones in functioning gallbladders who are poor surgical candidates, and for managing PBC. The medical applications extend to other cholestatic conditions where altering bile composition provides therapeutic benefit.
The significance of Actigall in modern therapeutics lies in its ability to fundamentally modify the hepatobiliary environment rather than simply masking symptoms. Unlike chenodiol, its predecessor which carried higher hepatotoxicity risks, Actigall offers a superior safety profile while effectively reducing cholesterol saturation index in bile.
2. Key Components and Bioavailability Actigall
Actigall’s composition centers on ursodiol as the sole active pharmaceutical ingredient, typically formulated in 300mg capsules for oral administration. The release form is immediate, with absorption occurring primarily in the small intestine through passive diffusion and active transport.
Bioavailability of Actigall ranges from 60-80% in fasting conditions, significantly enhanced when administered with food due to stimulated gallbladder contraction and bile flow. First-pass hepatic extraction is approximately 50%, with the remainder entering systemic circulation. The specific molecular structure—a 7β-hydroxy epimer of chenodeoxycholic acid—confers superior hydrophilicity and reduced cytotoxicity compared to endogenous bile acids.
We learned this the hard way with Thomas, a 68-year-old with recurrent choledocholithiasis. He’d been taking his Actigall at bedtime on an empty stomach “to avoid side effects,” but his gallstone dissolution was progressing slower than expected. When we switched him to dosing with his largest meal, follow-up ultrasound at 6 months showed nearly complete dissolution. The pharmacokinetics matter tremendously.
3. Mechanism of Action Actigall: Scientific Substantiation
How Actigall works involves multiple complementary pathways. Primarily, it reduces cholesterol saturation in bile by inhibiting intestinal cholesterol absorption and decreasing hepatic cholesterol secretion. Simultaneously, it promotes cholesterol crystal dissolution through micellar formation.
The mechanism of action extends to cytoprotective effects on hepatocytes and cholangiocytes. Actigall stabilizes mitochondrial membranes, inhibits apoptosis, and stimulates hepatobiliary secretion through post-transcriptional regulation of transporter proteins. Scientific research demonstrates it displaces more toxic endogenous bile acids like lithocholic acid from the enterhepatic circulation.
Think of it as replacing the “bad neighbors” in your bile acid neighborhood with “good citizens” that play nicely with liver cells. The effects on the body are both direct (cholesterol dissolution) and indirect (reduced inflammation and cellular injury).
4. Indications for Use: What is Actigall Effective For?
Actigall for Cholesterol Gallstone Dissolution
For radiolucent gallstones <20mm in diameter in functioning gallbladders, Actigall achieves complete dissolution in approximately 30-40% of patients within 6-24 months of continuous therapy. Stone composition matters—pure cholesterol stones respond best, while calcified or pigment stones are refractory.
Actigall for Primary Biliary Cholangitis
In PBC, indications for use focus on improving biochemical parameters (particularly alkaline phosphatase and bilirubin), delaying histological progression, and potentially improving transplant-free survival. The American Association for Liver Disease guidelines strongly recommend ursodiol at 13-15 mg/kg/day as first-line therapy.
Actigall for Other Cholestatic Conditions
Off-label applications include primary sclerosing cholangitis, intrahepatic cholestasis of pregnancy, cystic fibrosis-associated liver disease, and drug-induced cholestasis. The evidence base varies across these conditions, with strongest support for pregnancy-related cholestasis.
Actigall for Prevention of Gallstone Formation
During rapid weight loss (such as post-bariatric surgery), Actigall for prevention reduces gallstone formation from approximately 30% to 2-8% when administered at 600mg daily during the period of most rapid weight loss.
5. Instructions for Use: Dosage and Course of Administration
Dosage varies significantly by indication, requiring careful individualization:
| Indication | Daily Dosage | Frequency | Administration | Duration |
|---|---|---|---|---|
| Gallstone dissolution | 8-10 mg/kg | 2-3 divided doses | With meals | 6-24 months |
| Primary biliary cholangitis | 13-15 mg/kg | 2-4 divided doses | With meals | Lifelong |
| Gallstone prevention | 600 mg | Once daily or divided | With largest meal | During rapid weight loss period |
How to take Actigall consistently with meals is crucial for optimal efficacy. The course of administration should continue for at least 3 months after radiologically confirmed gallstone dissolution to prevent early recurrence.
Side effects are generally mild and infrequent (<5%), most commonly diarrhea, constipation, dyspepsia, and nausea—typically dose-related and transient.
6. Contraindications and Drug Interactions Actigall
Contraindications include known hypersensitivity to bile acids, non-functioning gallbladder, calcified gallstones, frequent biliary colic, and acute cholecystitis. Is it safe during pregnancy? Category B—generally considered safe, with particular utility in intrahepatic cholestasis of pregnancy.
Interactions with other medications primarily involve drugs that affect cholesterol metabolism or bile acid sequestrants. Cholestyramine, colestipol, and aluminum-based antacids may reduce Actigall absorption and should be administered at least 2-4 hours apart. Estrogens and clofibrate may counteract efficacy by increasing biliary cholesterol secretion.
We had a close call with Linda, 47, whose PBC was responding beautifully to Actigall until she started cholestyramine for refractory pruritus. Her liver enzymes rebounded within weeks until we realized she was taking both medications simultaneously. Spacing them resolved the issue, but it taught us to always review the complete medication list.
7. Clinical Studies and Evidence Base Actigall
The clinical studies supporting Actigall span four decades, with robust randomized controlled trials and meta-analyses. A landmark 1985 New England Journal of Medicine study demonstrated 30% complete gallstone dissolution at 6 months with 8-10 mg/kg/day versus 11% with placebo.
For PBC, the UDCA-PBC Study Group trial showed significant improvement in biochemical markers and delayed histological progression. More recently, the Global PBC Study Group analysis of 4,925 patients confirmed improved transplant-free survival with long-term ursodiol therapy, particularly when achieving biochemical response (normal bilirubin and ALP <1.67× ULN at 1 year).
Scientific evidence from hepatology guidelines consistently positions Actigall as first-line therapy for PBC and a viable alternative to cholecystectomy in selected gallstone patients. Physician reviews emphasize its excellent long-term safety profile, with some patients continuing therapy for over 20 years without significant adverse effects.
8. Comparing Actigall with Similar Products and Choosing a Quality Product
Actigall similar products include generic ursodiol formulations and the related obeticholic acid (Ocaliva) for PBC. Generic equivalents are bioequivalent to the branded product, though some clinicians report anecdotal differences in tolerability.
Comparison with obeticholic acid reveals complementary roles—Actigall remains first-line for PBC, while Ocaliva is reserved for inadequate responders. Which Actigall is better? The branded versus generic debate lacks robust evidence, though some patients report better tolerance with one formulation.
How to choose involves considering indication, cost, insurance coverage, and individual response. For gallstone dissolution, any high-quality ursodiol product should suffice, while for PBC, consistency in manufacturer might be preferable for long-term management.
9. Frequently Asked Questions (FAQ) about Actigall
What is the recommended course of Actigall to achieve results?
For gallstone dissolution, minimum 6 months with assessment by ultrasound. For PBC, lifelong therapy with biochemical monitoring at 3-6 month intervals initially.
Can Actigall be combined with other hepatology medications?
Yes, frequently combined with obeticholic acid in PBC non-responders, and safely used with most other medications except bile acid sequestrants without proper spacing.
How long until symptomatic improvement with Actigall?
Pruritus improvement in PBC often within 2-4 weeks, while biochemical response typically plateaus at 6-12 months.
Does Actigall cause weight gain?
No significant association with weight changes, though improved nutrition in chronic liver disease patients might lead to healthy weight normalization.
Can Actigall be used in children?
Yes, for pediatric cholestatic conditions with appropriate weight-based dosing and monitoring.
10. Conclusion: Validity of Actigall Use in Clinical Practice
The risk-benefit profile strongly favors Actigall in its approved indications, with decades of clinical experience supporting its efficacy and safety. For appropriate candidates, it provides a valuable non-surgical alternative for gallstone management and remains the foundation of PBC therapy.
The key benefit of Actigall lies in its multifactorial mechanism addressing both the biochemical abnormalities and cellular injury in cholestatic liver diseases. While not universally effective, it represents one of gastroenterology’s best-tolerated long-term therapies.
Looking back over 15 years of using this medication, I’m struck by how it’s transformed outcomes for patients like David, whom I’ve followed since his PBC diagnosis in 2010. He’s now 72, still on the same Actigall dose, with stable disease and excellent quality of life. Just last month, he told me, “This little capsule let me see my grandchildren grow up.” That’s the real evidence that transcends the clinical trials—the longitudinal follow-up showing decades of preserved liver function. We’ve had our share of non-responders, of course, and the ongoing debate in our hepatology group about when to add second-line agents continues. But for those who respond, Actigall remains one of our most dependable tools against progressive liver disease.